House Judiciary Committee Chairman Jim Jordan has sent letters to Pfizer's CEO, Dr. Albert Bourla, and former Global Head of Vaccines Research and Development, Dr. Philip Dormitzer, following claims that senior executives at Pfizer may have delayed the release of COVID-19 vaccine data to influence the 2020 presidential election.
According to a Wall Street Journal report from March 26, 2025, authorities have information from a former senior executive suggesting Pfizer withheld positive clinical trial results to impact the election outcome. The Journal identified Dr. Dormitzer as the source of this information, which he reportedly shared with his then-employer GSK plc in late 2024 after President Trump's re-election.
On April 9, 2025, the House Judiciary Committee reached out to GSK for further details regarding these allegations. GSK responded on April 16, 2025, indicating:
"In November 2024, shortly after the election, Dr. Dormitzer approached a representative from the GSK human resources team to speak about a potential relocation abroad. As the human resources representative recalls, in their meeting, Dr. Dormitzer was visibly upset; he requested that he be relocated to Canada due to concerns that he could be investigated by the incoming Trump Administration over his role in developing Pfizer's COVID-19 vaccine. According to the human resources representative, when asked what prompted his request, Dr. Dormitzer made a comment to the effect of: 'Let's just say it wasn't a coincidence, the timing of the vaccine.'"
GSK also informed that Dr. Dormitzer told employees "in late 2020," three senior members within Pfizer's R&D were involved in delaying clinical testing so it wouldn't conclude before election results were announced.
It remains unclear who within Pfizer R&D participated alongside Dr. Dormitzer in this decision-making process; however, he claimed that Pfizer’s CEO was not informed about any delay.
The full letters addressed to both Dr. Albert Bourla and Dr. Philip Dormitzer are available for public viewing.
